Cargando…

The SLC25A1-p53 mutant crosstalk

Detalles Bibliográficos
Autores principales:	Albanese, Chris, Avantaggiati, Maria Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586092/ https://www.ncbi.nlm.nih.gov/pubmed/26298092

Ejemplares similares

SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker
por: Kolukula, Vamsi K., et al.
Publicado: (2014)

The Mitochondrial Citrate Carrier SLC25A1/CIC and the Fundamental Role of Citrate in Cancer, Inflammation and Beyond
por: Mosaoa, Rami, et al.
Publicado: (2021)

Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH
por: Tan, Mingjun, et al.
Publicado: (2020)

Mutant p53 and sIL-1Ra
por: Bossi, Gianluca
Publicado: (2015)

Chromatin dysregulation by mutant p53
por: Pfister, Neil T., et al.
Publicado: (2016)

Targeting mutant p53 for cancer therapy
por: Oren, Moshe, et al.
Publicado: (2016)

Mutant p53—a potential player in shaping the tumor–stroma crosstalk
por: Stein, Yan, et al.
Publicado: (2019)

Degradation of mutant p53H175 protein by Zn(II) through autophagy
por: Garufi, A, et al.
Publicado: (2014)

How mutant p53 empowers Foxh1 fostering leukaemogenesis?
por: Amelio, Ivano
Publicado: (2019)

An expanded role for Caveolin-1 in brain tumors
por: Tanowitz, Herbert B., et al.
Publicado: (2013)

Flipping the “switch” on mutant p53 by zinc metallochaperones: how a brief pulse of zinc can reactivate mutant p53 to kill cancer
por: Yu, Xin, et al.
Publicado: (2019)

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer
por: Fernandez, Harvey R., et al.
Publicado: (2018)

Selective targeting of p53 gain-of-function mutants in cancer
por: Padmanabhan, Achuth
Publicado: (2018)

Small ceramide tames big p53 mutant beast
por: Hill, Ronald A., et al.
Publicado: (2020)

TP53 and MTOR crosstalk to regulate cellular senescence
por: Galluzzi, Lorenzo, et al.
Publicado: (2010)

Wiring the oncogenic circuitry: Pin1 unleashes mutant p53
por: Napoli, Marco, et al.
Publicado: (2011)

A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells
por: Garufi, Alessia, et al.
Publicado: (2013)

The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells
por: Waye, Sarah, et al.
Publicado: (2015)

The BRD7-P53-SLC25A28 axis regulates ferroptosis in hepatic stellate cells
por: Zhang, Zili, et al.
Publicado: (2020)

Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth
por: Aggarwal, M, et al.
Publicado: (2016)

A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis
por: Ferris, Margaret A., et al.
Publicado: (2022)

The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression
por: Cai, Bi-He, et al.
Publicado: (2023)

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2016)

Crosstalk between p53 and TGF-β Signalling
por: Elston, Rebecca, et al.
Publicado: (2012)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway
por: Naeem, Aisha, et al.
Publicado: (2022)

Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
por: Vikhanskaya, Faina, et al.
Publicado: (2007)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Big bones in p53 mutants
por: LeBrasseur, Nicole
Publicado: (2006)

Mutant p53 succumbs to starvation
por: Moon, Sung-Hwan, et al.
Publicado: (2013)

Mutant p53 partners in crime
por: Kim, Michael P, et al.
Publicado: (2018)

Mutant p53 in colon cancer
por: Nakayama, Mizuho, et al.
Publicado: (2018)

Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression
por: Eichelmann, Ann-Kathrin, et al.
Publicado: (2021)

Δ113p53/Δ133p53: survival and integrity
por: Chen, Jun, et al.
Publicado: (2015)

p53 tetramerization: at the center of the dominant-negative effect of mutant p53
por: Gencel-Augusto, Jovanka, et al.
Publicado: (2020)

Editor's Note on ‘Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53’
Publicado: (2023)

Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver
por: González-Moreno, Luis, et al.
Publicado: (2023)

The puzzling interplay between p53 and Sp1
por: Oppenheim, Ariella, et al.
Publicado: (2017)

Slc25a39 and Slc25a40 Expression in Mice with Bile Duct Ligation or Lipopolysaccharide Treatment
por: Kawase, Atsushi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_km8k23kagbm3bud8231inv7qnd